As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

Bayer going after Pfizer for patent infringement is a forerunner for widespread abuse of intellectual property claims in food ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual property developed by Monsanto, the crop science company the German company ...

Both Ford and Pfizer have very attractive dividend yields.

Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, U.S. health officials said Thursday. The strange ...

A Moderna spokesperson said the company is aware of the lawsuit and will defend itself. Spokespeople for Pfizer, BioNTech and Johnson & Johnson did not immediately respond to requests for comment.

The unprecedented changes have led to diminished vaccine usage, and created a drag that will likely dent revenues.

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

WASHINGTON — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients — revving up their immune systems to help fight tumors. People with advanced lung or skin ...